Trial intelligence / Profile preview

Phase II single-arm study of neratinib in advanced NSCLC with uncommon EGFR mutations

CTR20231827Phase 2Active

Sponsor

Convalife Pharmaceutical

Start

Jun 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1